2. Search Result
Search Result
Results for "

Natriuresis

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139037
    8-Aminoguanine

    		Endogenous Metabolite Metabolic Disease
    8-Aminoguanine is a endogenous purine. 8-Aminoguanine inhibits PNPase (purine nucleoside phosphorylase). 8-Aminoguanine induces diuresis/natriuresis/glucosuria .
    8-Aminoguanine
  • HY-106616
    Muzolimine

    BAY-g 2821; Edrul

    		 Sodium Channel Cardiovascular Disease
    Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive and natriuresis effects. Muzolimine can be used for the research of cardiovascular disease .
    Muzolimine
  • HY-B1203
    Fludrocortisone

    9α-Fludrocortisone; 9α-Fluorcortisol

    		 Mineralocorticoid Receptor Sodium Channel Inflammation/Immunology Cancer
    Fludrocortisone inhibits natriuresis. Fludrocortisone is a synthetic mineralocorticoid with anti-inflammatory activity. Fludrocortisone can be studied in research for small cell lung cancer with profound hyponatremia and acute neurological symptoms as well as aneurysmal subarachnoid hemorrhage .
    Fludrocortisone
  • HY-122560A
    VU0134992 hydrochloride
    3 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    VU0134992 hydrochloride is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 hydrochloride is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
    VU0134992 hydrochloride
  • HY-106616R
    Muzolimine (Standard)

    BAY-g 2821 (Standard); Edrul (Standard)

    		 Sodium Channel Reference Standards Cardiovascular Disease
    Muzolimine (Standard) is the analytical standard of Muzolimine. This product is intended for research and analytical applications. Muzolimine (BAY-g 282) is a slow and long lasting diuresis agent. Muzolimine produces a diuresis in the loop of Henle and also shows anti-hypertensive and natriuresis effects. Muzolimine can be used for the research of cardiovascular disease .
    Muzolimine (Standard)
  • HY-B1203R
    Fludrocortisone (Standard)

    9α-Fludrocortisone (Standard); 9α-Fluorcortisol (Standard)

    		 Reference Standards Mineralocorticoid Receptor Sodium Channel Inflammation/Immunology Cancer
    Fludrocortisone (Standard) is the analytical standard of Fludrocortisone. This product is intended for research and analytical applications. Fludrocortisone inhibits natriuresis. Fludrocortisone is a synthetic mineralocorticoid with anti-inflammatory activity. Fludrocortisone can be studied in research for small cell lung cancer with profound hyponatremia and acute neurological symptoms as well as aneurysmal subarachnoid hemorrhage .
    Fludrocortisone (Standard)
  • HY-W771063
    8-Aminoguanine-13C2,15N

    		Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    8-Aminoguanine- 13C2, 15N is the 13C- and 15N-labeled 8-Aminoguanine (HY-139037). 8-Aminoguanine is a endogenous purine. 8-Aminoguanine inhibits PNPase (purine nucleoside phosphorylase). 8-Aminoguanine induces diuresis/natriuresis/glucosuria .
    8-Aminoguanine-13C2,15N
  • HY-122282
    AZ11657312

    		Angiotensin Receptor Cardiovascular Disease
    AZ11657312 is a P2X7 receptor antagonist with activity to restore stress natriuresis. AZ11657312 significantly increased renal medullary perfusion, only in mice treated with angiotensin II. AZ11657312 improves tissue oxygenation by blocking P2X7R, especially in areas of the kidney that are underoxygenated. Administration of AZ11657312 increased sodium excretion up to sixfold while normalizing blood pressure .
    AZ11657312
  • HY-124687
    ROMK-IN-32

    		Potassium Channel Cardiovascular Disease
    ROMK-IN-32 is a renal outer medullary potassium channel (ROMK) inhibitor with an IC50 of 35 nM. ROMK-IN-32 also inhibits hERG with an IC50 of 22 μM .
    ROMK-IN-32
  • HY-122560
    VU0134992

    		Potassium Channel Cardiovascular Disease
    VU0134992 is the first subtype-preferring, orally active and selective Kir4.1 potassium channel pore blocker, with an IC50 of 0.97 µM. VU0134992 is 9-fold selective for homomeric Kir4.1 over Kir4.1/5.1 concatemeric channels (IC50=9 µM) at -120 mV .
    VU0134992
  • HY-15195
    Avosentan

    Ro 67-0565; SPP-301

    		 Endothelin Receptor Cardiovascular Disease Endocrinology
    Avosentan (Ro 67-0565; SPP-301) is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure .
    Avosentan
  • HY-15195R
    Avosentan (Standard)

    Ro 67-0565 (Standard); SPP-301 (Standard)

    		 Reference Standards Endothelin Receptor Cardiovascular Disease Endocrinology
    Avosentan (Standard) is the analytical standard of Avosentan (HY-15195). This product is intended for research and analytical applications. Avosentan is an orally active endothelin (ETA) receptor antagonist. Avosentan can block the ETA receptor, thereby reducing vascular contraction, and exerting a renal protective effect. Avosentan inhibits vascular contraction caused by ET-1 and alleviates the reduction in retinal and optic nerve head blood flow induced by it, lowering intraocular pressure in the glaucoma monkey model. Avosentan non-specifically blocks ETB receptors at high doses, inhibiting ETB-mediated diuresis and natriuresis, and may cause fluid retention. Avosentan can be used to reduce proteinuria with diabetic nephropathy, but induces significant fluid overload and congestive heart failure.
    Avosentan (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: